{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Aod-9604",
    "short_name": "AOD-9604",
    "aliases": [
      "aod",
      "hGH fragment 176-191"
    ],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Not FDA-approved for human therapeutic use; widely sold as research-grade peptide."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-17",
      "human_use_note": "AOD-9604 is not approved for human therapeutic use. Despite this, it is widely marketed and consumed as a research peptide, particularly in weight-loss contexts. No regulatory body currently authorizes it for medical treatment."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "YLRIVQCRSVEGSCGF",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 4,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "human_interventional",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Short-term human studies suggest limited adverse effects, but long-term safety data are sparse. The peptide mimics a fragment of human growth hormone, raising theoretical concerns around endocrine signaling, metabolic adaptation, and developmental exposure in adolescents.",
      "developmental_systems_of_concern": [
        "gh_igf",
        "metabolic",
        "puberty"
      ],
      "risk_score": 4
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "moderate",
          "evidence_grade": "human_interventional",
          "text": "AOD-9604 is a synthetic peptide derived from amino acids 176–191 of human growth hormone. It was developed to isolate the lipolytic (fat-metabolizing) effects of hGH without stimulating growth or insulin-like growth factor pathways.",
          "evidence_refs": [
            "E1",
            "E2"
          ]
        }
      ],
      "use_cases": [
        {
          "text": "These are the most common real-world reasons people look into this peptide, plus the context that tends to matter most (quality, expectations, and safety).",
          "title": "Use cases (real-world)"
        },
        {
          "text": "fat-loss interest driven by early mechanistic claims"
        },
        {
          "text": "metabolic curiosity in wellness communities (evidence limited)"
        },
        {
          "text": "often discussed in weight-management stacking conversations (anecdotal)"
        }
      ],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "subcutaneous",
          "unit": "mcg",
          "min": 250,
          "max": 500,
          "frequency": "daily",
          "duration": "up to 12 weeks",
          "population_group": "general",
          "notes": "Descriptive only. Observed in clinical studies; not instructions.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Use during adolescence may interfere with normal endocrine signaling and metabolic regulation. Long-term developmental effects have not been studied and may be irreversible.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [
        {
          "text": "Interactions here are category flags — they’re meant to help you ask better questions and avoid obvious conflicts. They are not a dosing guide.",
          "title": "Interaction summary"
        },
        {
          "text": "Drug-class flags to review:"
        },
        {
          "text": "diabetes-glucose-lowering"
        },
        {
          "text": "If you’re on cardiovascular, anticoagulant/antiplatelet, serotonergic, or immunomodulating meds/supplements, treat uncertainty as a reason to slow down and verify with a clinician."
        }
      ],
      "current_outlook_bullets": [
        "a synthetic peptide derived from amino acids 176–191 of human growth hormone",
        "it was developed to isolate the lipolytic (fat-metabolizing) effects of hGH without stimulating growth or insulin-like growth factor pathways",
        "weight-loss support (commonly discussed)",
        "metabolic health support (anecdotal)",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "A double-blind, placebo-controlled study of AOD-9604 for obesity",
        "source_type": "pubmed",
        "source_id": "15615612",
        "url": "https://pubmed.ncbi.nlm.nih.gov/15615612/",
        "published_date": "2005-01-01",
        "evidence_grade": "human_interventional",
        "notes": "Human trial evaluating weight-loss effects and safety over 12 weeks.",
        "year": 2004
      },
      {
        "id": "E2",
        "title": "Lipolytic domain of human growth hormone",
        "source_type": "pubmed",
        "source_id": "12183452",
        "url": "https://pubmed.ncbi.nlm.nih.gov/12183452/",
        "published_date": "2002-01-01",
        "evidence_grade": "unknown",
        "notes": "Identified the 176–191 fragment responsible for fat metabolism signaling.",
        "year": 2002
      }
    ],
    "changelog": [
      {
        "date": "2026-01-17",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for AOD-9604",
        "detail": "Created first alphabetical peptide entry with human and mechanistic evidence.",
        "evidence_refs": [
          "E1",
          "E2"
        ]
      }
    ],
    "meta": {},
    "topics": {
      "primary": [
        "topic_fat_loss_metabolism"
      ]
    },
    "slug": "aod-9604"
  },
  "canonical_name": "Aod-9604",
  "interactions": {
    "drug_classes": [
      "diabetes-glucose-lowering"
    ],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "bottom_line": "AOD-9604 is discussed for fat-loss and metabolic goals. Human outcomes are not well-established, so real-world expectations should be conservative.",
    "benefits": [
      "fat-loss interest driven by early mechanistic claims",
      "metabolic curiosity in wellness communities (evidence limited)",
      "often discussed in weight-management stacking conversations (anecdotal)"
    ],
    "side_effects_common": [
      "headache",
      "nausea or stomach upset",
      "sleep disruption in sensitive users"
    ],
    "side_effects_serious": [
      "chest pain, fainting, or severe shortness of breath",
      "severe allergic reaction symptoms (hives, facial swelling, trouble breathing)"
    ],
    "who_should_be_cautious": [
      "people with diabetes or unstable blood sugar control",
      "people with cardiovascular disease or uncontrolled blood pressure",
      "pregnant or breastfeeding individuals",
      "adolescents (developmental risk plus limited evidence)"
    ],
    "schema_version": "practical_block_v1"
  }
}
